RE:BT Global Growth Monthly Report This has been my thinking all along. There is definitely a disconnect in the market that fails to recognize Medx's potential.
If you read through any of the marketing materials for DermTech, you will see that all of the facts in terms of the size of the melanoma detection market and the growth potential for for their technology is basically the same for Medx.
IMO a huge reason for the difference in share price is in the marketing and promotion of these two companies. DermTech has contracted The Motley Fool to promote their stock, meanwhile Medx has done a horrible job at getting the word out there.
The Medx website is so lacking that one cannot find the most basic information. Such as "How many melanomas has Medx technology detected to date?" A metric that could easily raise their profile amongst the investing public.
I hope this changes once they announce their "big deal" with Shopper's Drug Mart or the like that Mike has made appear so imminent during every interview during the last 6 months.